So in the ESMO Asia 2025, there have been a presentation of the phase three clinical trial, the Luminet one. So it’s a study that was conducted in China. The population that is going to be recruited were the patients with the GEP net, grade 1 to grade 2. Most of the patients belong to the pancreatic net, and a small percentage belong to the small bowel net. And the control arm was four cycles of the Lutetium dotatate, while the control arm was the high dose of octreotide LAR, 60 milligrams every four weeks...
So in the ESMO Asia 2025, there have been a presentation of the phase three clinical trial, the Luminet one. So it’s a study that was conducted in China. The population that is going to be recruited were the patients with the GEP net, grade 1 to grade 2. Most of the patients belong to the pancreatic net, and a small percentage belong to the small bowel net. And the control arm was four cycles of the Lutetium dotatate, while the control arm was the high dose of octreotide LAR, 60 milligrams every four weeks. So the primary endpoint was the progression-free survival. And the overall survival was the secondary endpoint. So the key results showed that the use of the Lutetium Dotatate for four cycles was associated with a remarkable and statistically significant improvement in the progression-free survival with a hazard ratio of 0.06, and the median PFS was not reached at the time of analysis versus the 5.6 months in the control arm. The overall survival benefit was not yet seen, but because of the immaturity of the overall survival curves. Overall, the treatment were well tolerated with grade 3 or above adverse events 42.9%. So these studies confirmed the role of the PRRT in those patients with progressive GEP net, and this will likely become the standard treatment in China for those patients with a progressive grade 1 to 2 GEP net.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
